

North Central Cancer Treatment Group

N0779: Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib (PS-341)
in Patients with Recurrent Glioblastoma Multiforme

Status Change – January 29, 2010

NOTICE OF STATUS CHANGE

This study is permanently closed to patient accrual effective Friday, January 29, 2010. Patient entry will not be allowed after Thursday, January 28, 2010 at 4:30 CST. NOTE: If you already have a patient in the pre-registration component, they will be allowed to continue to registration if eligible.

The study is closed per study design. Patients currently on study should be followed according to the protocol.

Please retain this notice with the protocol.